Member Info for Ivyspivey

Hi US I know it was a round table panel discussion featuring most of AB omoany�s. There may have been presentations but not totally sure.The audience were mainly institutional investors based in US so unless there is some publication I fear we will not get any information but I understand it was a good event for MTFB

Nice to see SP settled back after early fall. The shelf listing should not be a surprise as It is the standard way for Nasdaq Biotech Company�s to access capital should they require it as an option.Over 70 Company�s in the last 6 months have already put this facility in place. MTFB could not do this until they had completed 12 months of US listing. The RNS was quite explicit in saying there were no specific plans to use this facility and I see it purely as a way to maintain future options and as a very prudent step. My understanding also is that the Cantors AB summit panel discussion was very good and a number of institutional investors present. A note from Cantors has been sent out but only to institutional investors ATB

https://fb.me/K184vJZf Nice mention on Shard along with IMM and AMYT Today�s news imo is about having options and again is a good sign in the confidence of the BOD in securing the future Approval of Iclaprim. All I look at is does MTFB spend money wisely on trials etc to advance the drug and build value.An overwhelming yes from me

IanB. Absolutely it is about validation by important patient advocacy group and grant is unimportant. In new presentation they talk about Partnership Opportunity for CF.

Of course Hannibal. The point I was making is that they do not need any upfront payments from say a non US partner to complete their 2018 plans. Of course they need non US partner/s to commercialise Iclaprim but they would not have started HABP trial unless they were totally confident of one getting Approval for ABSSSI and two being able to complete HABP. For both of these to happen you need to start selling Iclaprim either as a combination of US and non US efforts IR a GLBAL deal.

They are starting in 1H 2018 but that is how long trial takes They could have got through to revenue stage for ABSSSI and can initiate HABP with Hercules money and can of course complete the HABP with ABSSSI revenues.

Few points on HABP Yes phase 2 compared to Vancomycin one of 2 SOC(Standard of Care) Drugs was very favourable and especially important at lower dose rate so less safety concerns as the mortality and morbidity rate amongst these patients is very high. Iclaprim particularly concentrates in lung tissue very quickly and is very effective.You should not underestimate this market opportunity as it is all about hospitalised patients and although numbers are smaller than ABSSSI I would expect Iclaprim to get much higher market share and also patients stay in hospital longer. Very important point in new presentation is the mention of significant synergy from a commercial viewpoint between ABSSSI and HABP. The Inspire(HABP phase 3) trials will take longer to complete 3-4 years but unde 21srpt Century Cures Act may only be necessary for one main trial

http://ir.motifbio.com/phoenix.zhtml?c=254416&p=irol-faq In case anyone is interested

Fully agree is positive and is more about US sites raising their profile and attract interest. Is high reward but totally rejected high risk.Yes if Iclaprim did not get Approved then it is risky but just think chance of success us extremely high. Suppose any AIM stock is risky when compared to investing in pharma with multi billion marke caps

But totally fails to understand what MTFB is all a out and positioning of Iclaprim

http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9Njg2MzMyfENoaWxkSUQ9Mzk2NTYzfFR5cGU9MQ==&t=1

Hi PK, Yes have a bit in N4P and IMM but lot more in SCLP and much much bigger amount here.That is my Bio pharma stocks plus the test lol

Sorry should have said 17m shares originally

24 April 2017 Motif Bio plc ("Motif Bio" or the "Company") Notification of change in holding of significant shareholder Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that it was informed on 21 April 2017 by Sabby Healthcare Master Fund Ltd ("Sabby") that as at 10 April 2017, Sabby's interest in shares in the Company to which voting rights are attached, being ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares"), had fallen from an interest in 17,191,980 Ordinary Shares (held by way of American Depositary Shares ("ADSs")), representing 9.52% of the Company's issue share capital, to an interest in 5,887,050 Ordinary Shares (held by way of 157,698 ADSs and 2,733,090 Ordinary Shares), representing 3% of the Company's issued share capital.

No confusion it states previous position 19m shares and present position none. They sold 12 months ago see RNSs and also sold their warrants MTFBW traded in Nasdaq. Leas-the warrant exercise today relates to some issued at 20p which were the ones done in April 2015 as part of AIM IPO. All other warrants were issued at 32p

Shabby sold out a year ago

Hi Sellon, Really is only indicated for Gram positive bacteria but they are absolutely key for ABSSSI and also HABP. There is a big need for new ABs effective vs Gram negative such as E coli/salmonella and others and it will require other compounds than Iclaprim. The important point is that MTFB are targeting the biggest unmet need markets hence ABSSSI( renally impaired) and HABP.The crisis and need for new ABs will be met only by several new compounds and approaches as well as reducing use of currentvABs in human and animal use. A completely new class of AB is likely to be used sparingly as drug of last resort whether Gram positive/negative. MTFB have avoided this pathway by a very specific target market approach. They will of course look to develop other ABs to compete in the Gram negative space

Iclaprim has demonstrated limited activity vs Gram negative bacteria and iscmsinly vs MSSA and MRSA which are both Gram positive. So apart from in combination it will not be the answer to the major global issue of resistance in Gram negative bacteria. So would not get too cited about it in this spectrum of activity

Company�s Appearing Company Name Achaogen, Inc. Amplyx Pharmaceuticals Inc. Aridis Pharmaceuticals, Inc. Arsanis, Inc. Basilea Pharmaceutica AG Cardiome Pharma Corp. Cidara Therapeutics Inc. ContraFect Corp Destiny Pharma PLC Iterum Therapeutics Melinta Therapeutics Inc. Motif Bio PLC Nabriva Therapeutics plc Paratek Pharmaceuticals, Inc. SCYNEXIS Inc Spero Therapeutics Inc Tetraphase Pharmaceuticals Inc. Ticker AKAO Private Private ASNS SWX: BSLN CRME CDTX CFRX LON: DEST Private MLNT LON: MTFB NBRV PRTK SCYX SPRO TTPH

OK but as under Fastrack it is maximum 6 months for review I expect it to take that long as FDA wont want to make it shorter even if no real worries. We know new ABs are needed but not like MTFB can launch any quicker and it s not a desperately needed treatment such as a new Vaccine vs Ebola or Zika etc so no massive pressure to Approve even earlier